Trial record 2 of 19 for:
sangamo
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03041324 |
|
Recruitment Status :
Recruiting
First Posted : February 2, 2017
Last Update Posted : January 29, 2019
|
Sponsor:
Sangamo Therapeutics
Information provided by (Responsible Party):
Sangamo Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2021 |
| Estimated Study Completion Date : | February 2022 |